Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | CBLB | Q13191 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716637 | 0.87 | ABCG2 (0.36) | SMN1; SMN2PSMD14HSP90AA1MMP2MC4R | |
| SCHEMBL17472220 | 0.80 | DNM1 (0.53) | SMN1; SMN2KMT2AATMMAPK1MEN1 | |
| SCHEMBL13852367 | 0.80 | PSMD14 (0.45) | SMN1; SMN2PSMD14HSP90AA1MMP2MC4R | |
| SCHEMBL16319751 | 0.79 | ZDHHC20 (0.46) | SMN1; SMN2CBLBPSMD14HSP90AA1MMP2 | |
| SCHEMBL31598809 | 0.78 | DNM1 (0.51) | SMN1; SMN2PSMD14HSP90AA1MMP2MC4R | |
| Bromide SCHEMBL14637403 | 0.78 | ZDHHC20 (0.45) | SMN1; SMN2CBLBPSMD14HSP90AA1MMP2 | |
| Hydrochloric Acid SCHEMBL17786220 | 0.77 | MAPK1 (0.40) | SMN1; SMN2KDM4EMAPK1MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL29598620 | 0.77 | HPGD (0.37) | SMN1; SMN2KDM4EHSP90AA1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL28467907 | 0.76 | PSMD14 (0.41) | SMN1; SMN2PSMD14HSP90AA1MMP2MC4R | |
| SCHEMBL18314761 | 0.76 | BCHE (0.40) | SMN1; SMN2KDM4EF13A1PSMD14HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131223-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | INSIGHT HEALTH LIMITED | 2020-04-30 | — | — | US | claimed |
| US-11629166-B2 | Compound for treating clostridium difficile | ASTON UNIVERSITY (GB) | 2023-04-18 | — | — | US | disclosed |
| US-20200131223-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | INSIGHT HEALTH LIMITED | 2020-04-30 | — | — | US | disclosed |
| US-20170320906-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | INSIGHT HEALTH LIMITED (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-3223855-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | Aston University (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016083819-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | ASTON UNIVERSITY (GB) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629166-B2 | Compound for treating clostridium difficile | DSTN, DAD1, DDOST | SMN1; SMN2 4725/4885KDM4E 3697/4885F13A1 3760/4885 |
| US-20170320906-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | DSTN, DAD1, DDOST | SMN1; SMN2 4725/4885KDM4E 3697/4885F13A1 3760/4885 |
| US-20200131223-A1 | COMPOUND FOR TREATING CLOSTRIDIUM DIFFICILE | DSTN, DAD1, DDOST | SMN1; SMN2 4725/4885KDM4E 3697/4885F13A1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.